Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Siglec-7 tetramers characterize B-cell subpopulations and leukemic blasts

(2012) Friederike Gieseke et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors

(2012) Robert E. White et al.   JOURNAL OF CLINICAL INVESTIGATION

Colonic Epithelial Cells Express Specific Ligands for Mucosal Macrophage Immunosuppressive Receptors Siglec-7 and -9

(2012) K. Miyazaki et al.   JOURNAL OF IMMUNOLOGY

Targeting Siglecs—A novel pharmacological strategy for immuno- and glycotherapy

(2011) Camilla Jandus et al.   BIOCHEMICAL PHARMACOLOGY

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

(2011) A. Curti et al.   BLOOD

Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9

(2010) Mariko Ohta et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence

(2010) T. Strowig et al.   BLOOD

Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education

(2010) N. K. Bjorkstrom et al.   BLOOD

CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset

(2010) S. Lopez-Verges et al.   BLOOD

Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells

(2010) Y. Kawasaki et al.   GLYCOBIOLOGY

Cell Death Modulation by Intravenous Immunoglobulin

(2010) Stephan von Gunten et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Sialylation of 3-Methylcholanthrene-Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting

(2010) M. Cohen et al.   JOURNAL OF IMMUNOLOGY

Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes

(2010) Jennifer A. Belisle et al.   Molecular Cancer

The Sialome—Far More Than the Sum of Its Parts

(2010) Miriam Cohen et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Basic and Clinical Immunology of Siglecs

(2009) Stephan von Gunten et al.   Annals of the New York Academy of Sciences

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: Clues in the ongoing search for new tumor markers

(2009) Reiji Kannagi et al.   CANCER SCIENCE

Immune infiltration in human tumors: a prognostic factor that should not be ignored

(2009) F Pagès et al.   ONCOGENE

Siglecs as targets for therapy in immune-cell-mediated disease

(2009) Mary K. O’Reilly et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future

(2008) Marc Daëron et al.   IMMUNOLOGICAL REVIEWS

Protein-glycan interactions in the control of innate and adaptive immune responses

(2008) Yvette van Kooyk et al.   NATURE IMMUNOLOGY

NK cells and cancer immunosurveillance

(2008) I Waldhauer et al.   ONCOGENE

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

(2008) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA